FindTrial
Sign In

Prospective, multicenter, open-labeled, phase II study of clinical effect of the combination of metformin and standard chemotherapy in patient with newly diagnosed with T-cell lymphoma and the role of AMP-activated protein kinase (AMPK)

Prospective, multicenter, open-labeled, phase II study of clinical effect of the combination of metformin and standard chemotherapy in patient with newly diagnosed with T-cell lymphoma and the role of AMP-activated protein kinase (AMPK)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CRIS
Registry ID
KCT0007442
Enrollment
60
Registered
2022-06-28
Start date
2022-08-01
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : not applicable

Sponsors

Kyungpook National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: not applicable

Exclusion criteria

Exclusion criteria: not applicable

Design outcomes

Primary

MeasureTime frame
Event free survival—

Secondary

MeasureTime frame
Overall survival—

Countries

Korea, Republic of

Contacts

Public ContactDong Won Baek

Kyungpook National University Hospital

vroom21@hanmail.net+82-53-200-5570

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026